Asteria Health recalled 153,498 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. The recall affects lots expiring between June and September 2026. Consumers and healthcare providers must stop using the product immediately.
Presence of Foreign substance - potential presence of metal particulate matter
Consumers and healthcare providers should stop using this product immediately. Contact F.H. INVESTMENTS, Inc. (dba Asteria Health) or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Testosterone, 100 mg, 1 Sterile Pellet. Asteria Health manufactured the product at 432 Industrial Ln, Birmingham, AL 35211. The affected lot numbers include 251000132, 251000142, 251000144, and others, with expiration dates ranging from June 16, 2026, to September 12, 2026.
The recall stems from the potential presence of metal particulate matter in the testosterone pellets. This contamination poses significant health risks, as ingested metal can lead to serious health complications.
No specific incidents or injuries have been reported related to this recall. However, the risk of metal contamination is classified as high, warranting immediate action.
Consumers should stop using the recalled testosterone pellets immediately. Contact F.H. INVESTMENTS, Inc. or your healthcare provider for guidance on returning the product.
For further information, consumers can contact F.H. INVESTMENTS, Inc. at their official website or through the FDA's recall notification page.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.